TAVST01 / Tikva Allocell - LARVOL DELTA

Tikva Allocell…announced the closing of an $8 million Series A financing led by Kantharos Capital (PRNewswire) - "Proceeds will fund IND-enabling activities and a planned year-end 2026 Investigational New Drug (IND) submission for TAVST01, Tikva's lead candidate for B7-H3-positive solid tumors. Subject to regulatory clearance, the company plans to initiate a Phase 1 clinical trial in patients with advanced B7-H3-positive cancer at sites in Singapore and the United States."

Financing • IND • New P1 trial • Solid Tumor